Advanced Biomed Inc. (ADVB)

Advanced Biomed Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Selling, General & Admin	1.63	1.66	1.69	0.75	0.1
Research & Development	0.88	0.88	1.38	1.62	1.73
Operating Expenses	2.51	2.54	3.07	2.37	1.84
Operating Income	-2.51	-2.54	-3.07	-2.37	-1.84
Interest & Investment Income	0.05	0.05	0.02	0	0
Currency Exchange Gain (Loss)	-0.9	-0.29	-0.51	-	-
Other Non Operating Income (Expenses)	-0	0	-0.02	-0.04	-0
EBT Excluding Unusual Items	-3.37	-2.78	-3.58	-2.41	-1.84
Impairment of Goodwill	-	-	-	-1.62	-
Gain (Loss) on Sale of Assets	-	-	-0.15	-	-
Pretax Income	-3.37	-2.78	-3.73	-4.03	-1.84
Net Income	-3.37	-2.78	-3.73	-4.03	-1.84
Net Income to Common	-3.37	-2.78	-3.73	-4.03	-1.84
Shares Outstanding (Basic)	20	20	20	14	11
Shares Outstanding (Diluted)	20	20	20	14	11
Shares Change (YoY)	0.70%	0.32%	40.55%	23.74%	-
EPS (Basic)	-0.17	-0.14	-0.19	-0.28	-0.16
EPS (Diluted)	-0.17	-0.14	-0.19	-0.28	-0.16
Free Cash Flow	-4.82	-2.2	-3.17	-1.63	-0.5
Free Cash Flow Per Share	-0.24	-0.11	-0.16	-0.12	-0.04
EBITDA	-2.21	-2.27	-2.84	-2.26	-1.78
D&A For EBITDA	0.3	0.27	0.23	0.11	0.06
EBIT	-2.51	-2.54	-3.07	-2.37	-1.84

Updated Jan 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q